Archive for April 29th, 2011

CBRX submits PROCHIEVE NDA, SGMO data release update

Apr 29, 2011 No Comments by

Sangamo BioSciences, Inc. (Nasdaq: SGMO) today said they expect top-line efficacy data of their Phase 2b Clinical Trial in Diabetic Neuropathy in 2H 2011. Previous guidance released in February was for data during 4Q 2011. Columbia Laboratories, Inc. (Nasdaq: CBRX), and Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that they had submitted their NDA for […]

Daily News Read more